Study to Assess the Prognostic Value of the Antithrombin III in the Acute Pancreatitis (AT-PROPANC)

Study Overview
=================
Brief Summary
-----------------
This is an epidemiological, observational, prospective, multicentric study in 400 adult patients admitted to hospital for mild acute pancreatitis to to assess the prognostic value of the antithrombin III in the development of moderate or severe acute pancreatitis.

Detailed Description
-----------------
This is an epidemiological, observational, prospective, multicentric study in 400 adult patients admitted to hospital for mild acute pancreatitis to to assess the prognostic value of the antithrombin III in the development of moderate or severe acute pancreatitis. In the context of clinical practice of general surgery and apparatus digestive services, patients entering with mild acute pancreatitis will be asked to participate in the study and if so, they will sign the informed consent. On admission, demographic and anthropometric data of the patient will be recorded, as well as medical history, patient's admission data and vital signs. Patient's blood will be drawn for analysys and the risk of organ failure will be measured by modified Marshall and Apache II scales. The assessments and procedures performed are the standard practice at the center. At 24 hours (± 3 hours) and at 7 days (or nine days to avoid weekends) after admisison, vital signs will be recorded, laboratory tests will be performed and the risk of organ failure will be measured by modified Marshall and Apache II scales. At discharge of the patient (regardless of when it occurs), the outcome of the acute pancreatitis will be recorded. . Those patients discharged within the first month after admission will be visited or called (according to standard practice at the center) one month after arrival, to record follow-up data, including health condition, readmissions and abdominal pain evaluation by visual analog scale.

Official Title
-----------------
Epidemiologic , Observational, Prospective Study to Assess the Prognostic Value of the Antithrombin III in the Development of Moderate or Severe Acute Pancreatitis (AT-PROPANC)

Conditions
-----------------
Acute Pancreatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with mild acute pancreatitis according to seriousness criteria established by Banks et al, 2013. Patients of either sex aged ≥ 18 years . Patients who have given their written informed consent Exclusion Criteria: Patients with exacerbated chronic pancreatitis. Patients with coagulation disorders (congenital and acquired antithrombin deficiency) . Patients with liver cirrhosis. Pregnant patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| antithrombin III levels vs maximum seriousness grade of acute pancreatitis | Levels of antithrombin III at admission and at 24h will be related with maximum seriousness grade of acute pancreatitis reached during patient's admission at site by logistic regression models | At Admission and at 24h | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| result of modified Marshall and Apache II scales |  | Admission and at 24h | 
| antithrombin III levels vs mortality | Levels of antithrombin III at admission and at 24h will be related with mortality rates by logistic regression models | From date of admission until the end of study or date of death from any cause, whichever came first, assessed up to 1 month | 
| antithrombin III levels vs organic failure | Levels of antithrombin III at admission and at 24h will be related with organic failure rates by logistic regression models | From date of admission until the end of study or date of organic failure, whichever came first, assessed up to 1 month | 
| antithrombin III levels vs necrosis and infection rates | Levels of antithrombin III at admission and at 24h will be related with necrosis and infection rates by logistic regression models | From date of admission until the end of study or date of necrosis or infection diagnosis, whichever came first, assessed up to 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute pancreatitis